These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 28963566)

  • 1. Compilation of online resources of relevance to 'Spinraza and advanced therapies: a stakeholder special' issue of Gene Therapy.
    Prakash V; Yáñez-Muñoz RJ
    Gene Ther; 2017 Sep; 24(9):599. PubMed ID: 28963566
    [No Abstract]   [Full Text] [Related]  

  • 2. Market access of Spinraza (Nusinersen) for spinal muscular atrophy: intellectual property rights, pricing, value and coverage considerations.
    Simoens S; Huys I
    Gene Ther; 2017 Sep; 24(9):539-541. PubMed ID: 28880019
    [No Abstract]   [Full Text] [Related]  

  • 3. New Therapy for Spinal Muscular Atrophy Offers Modest Bang for Pharamaceutical Buck.
    Morrow T
    Manag Care; 2017 Feb; 26(2):36-37. PubMed ID: 28271991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spinraza-the patient perspective.
    Madipalli S
    Gene Ther; 2017 Sep; 24(9):501-502. PubMed ID: 28880018
    [No Abstract]   [Full Text] [Related]  

  • 5. Spinraza-a rare disease success story.
    Prakash V
    Gene Ther; 2017 Sep; 24(9):497. PubMed ID: 28963567
    [No Abstract]   [Full Text] [Related]  

  • 6. Nusinersen (Spinraza) for spinal muscular atrophy.
    Med Lett Drugs Ther; 2017 Mar; 59(1517):50-52. PubMed ID: 28323809
    [No Abstract]   [Full Text] [Related]  

  • 7. Gene Therapy, more than ever-a new vision for the journal.
    Yáñez-Muñoz RJ
    Gene Ther; 2017 Sep; 24(9):493-494. PubMed ID: 28963565
    [No Abstract]   [Full Text] [Related]  

  • 8. FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating Oligonucleotides.
    Aartsma-Rus A
    Nucleic Acid Ther; 2017 Apr; 27(2):67-69. PubMed ID: 28346110
    [No Abstract]   [Full Text] [Related]  

  • 9. [Can you patent the sun?].
    Slørdal L
    Tidsskr Nor Laegeforen; 2018 Apr; 138(7):. PubMed ID: 29663751
    [No Abstract]   [Full Text] [Related]  

  • 10. Spinal muscular atrophy: A modifiable disease emerges.
    Fitzgerald DA; Abel F; Jones KJ; Farrar MA
    Paediatr Respir Rev; 2018 Sep; 28():1-2. PubMed ID: 30414816
    [No Abstract]   [Full Text] [Related]  

  • 11. Ethical Challenges Confronted When Providing Nusinersen Treatment for Spinal Muscular Atrophy.
    Burgart AM; Magnus D; Tabor HK; Paquette ED; Frader J; Glover JJ; Jackson BM; Harrison CH; Urion DK; Graham RJ; Brandsema JF; Feudtner C
    JAMA Pediatr; 2018 Feb; 172(2):188-192. PubMed ID: 29228163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. News Feature: Gene therapy successes point to better therapies.
    Dolgin E
    Proc Natl Acad Sci U S A; 2019 Nov; 116(48):23866-23870. PubMed ID: 31772140
    [No Abstract]   [Full Text] [Related]  

  • 13. Nusinersen helps restore walking ability in childhood spinal muscular atrophy.
    Sugimoto M; Aiba K; Koyama N; Yokochi K; Nishio H
    Pediatr Int; 2019 Jul; 61(7):728-729. PubMed ID: 31290219
    [No Abstract]   [Full Text] [Related]  

  • 14. Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy.
    Corey DR
    Nat Neurosci; 2017 Apr; 20(4):497-499. PubMed ID: 28192393
    [No Abstract]   [Full Text] [Related]  

  • 15. [Nusinersen in the treatment of spinal muscular atrophy].
    Sinkó G; Kiss Z; Kalman B
    Ideggyogy Sz; 2018 Mar; 71(3-04):90-94. PubMed ID: 29889467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Designing Effective Antisense Oligonucleotides for Exon Skipping.
    Shimo T; Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mechanisms of action and patentability of therapeutic oligonucleotides].
    Crouvezier N; Marie AC; Moumné L
    Med Sci (Paris); 2023 Feb; 39(2):111-118. PubMed ID: 36799745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-Nusinersen Hospitalization Costs of Children With Spinal Muscular Atrophy.
    Lee M; França UL; Graham RJ; McManus ML
    Pediatr Neurol; 2019 Mar; 92():3-5. PubMed ID: 30591237
    [No Abstract]   [Full Text] [Related]  

  • 19. Cure SMA and our patient community celebrate the first approved drug for SMA.
    Glascock J; Lenz M; Hobby K; Jarecki J
    Gene Ther; 2017 Sep; 24(9):498-500. PubMed ID: 28504658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Translational development of splice-modifying antisense oligomers.
    Fletcher S; Bellgard MI; Price L; Akkari AP; Wilton SD
    Expert Opin Biol Ther; 2017 Jan; 17(1):15-30. PubMed ID: 27805416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.